Florida Blue Cross Blue Shield February 2018 Medical Policy Updates

Click here to view the Florida Blue Cross Blue Shield Medical Policy Updates »

February 2018 Medical Policy Updates:

New:

• Dopamine Transporter Imaging with Single-Photon Emission Computed Tomography

Revised:

• Adoptive Immunotherapy – Revision: updated description section, position statement section, related guidelines, index terms, and references.
• Alpha1-Proteinase Inhibitors (Human) – Review and revision to guideline; consisting of updating position statement, description, dosing, and references.
• Benralizumab (Fasenra) – Review of guideline; no changes.
• Bosutinib (Bosulif™) Tablets – Review and revision to guideline consisting of updates to description, dosage/administration, position statement, billing/coding, other, and references sections.
• Brachytherapy – Oncologic Applications – Revision; updated position statement, ICD-10 diagnoses codes and definitions. Added position statement for lung cancers (non-small cell and small cell) metastatic lesions in the lung and head and neck cancer.
• Cryosurgical Ablation of Miscellaneous Solid Tumors Other Than Liver, Dermatologic, or Prostate Tumors – Review; position statement section and references updated.
• Dasatinib (Sprycel®) Tablets – Review and revision to guideline consisting of updates to description, position statement, dosage/administration, billing/coding, definitions, other, and references sections.
• Denosumab (Prolia™, Xgeva™) Injection – Review and revision to guideline; consisting of updating position statement, description, dosing, warnings, coding, and references.
• FDG-SPECT – Review; no change in position statement. Updated references.
• Fractionation and Radiation Therapy – Update position statement, definitions and references. Added position statement for lung cancer (non-small cell).
• Genetic Testing – Revision; position statements, test names, and references updated.
• Genetic Testing for Hereditary Breast or Ovarian Cancer – Revision; position statements and references updated.
• P. Acthar® Gel (repository corticotropin) – Review and revision to guideline; consisting of updating references.
• Hereditary Angioedema Drug Therapy – Review to guideline; updated references.
• Ibandronate IV (Boniva®) – Review and revision to guideline; consisting of updating position statement and references.
• Image-Guided Radiation Therapy for Treatment Planning and Delivery – Revision; updated position statement and definitions.
• Imatinib Mesylate (Gleevec®) Tablets – Review and revision to guideline consisting of updates to description, position statement, precautions, billing/coding, and references sections.
• Intensity-Modulated Radiation Therapy (IMRT) – Revision; updated position statement, ICD-10 diagnoses codes, program exceptions and definitions.
• Magnetic Resonance Imaging (MRI) Orbit, Face, Temporomandibular Joint (TMJ) and Neck – Revision; updated and revised position statement (orbit, face, neck, TMJ, sinus). Updated program exceptions and references.
• Mepolizumab (Nucala®) – Revison to guideline; consisting of position statement, coding, references.
• Minimally Invasive Fusion Techniques – Scheduled review. Revised description section. Added coverage criteria for minimally invasive sacroiliac joint fusion/stabilization. Revised definitions and related guidelines sections. Updated references.
• Nilotinib (Tasigna®) Capsules – Review and revision to guideline consisting of updates to description, position statement, dosage/administration, billing/coding, definitions, and references sections.
• Omacetaxine Mepesuccinate (Synribo™) Injection – Review and revision to guideline consisting of updates to description, position statement, definitions, related guidelines and references sections.
• Omalizumab (Xolair®) – Revison to guideline; consisting of position statement, references.
• Ponatinib (Iclusig®) Tablets – Review and revision to guideline consisting of updates to description, position statement, dosage/administration, precautions, related guidelines, and references sections.
• Proton Beam Therapy – Reviewed; revised position statement. Added position statement for central nervous system (CNS) tumors in children. Updated definitions and references.
• Reslizumab (Cinqair®) IV infusion – Revison to guideline; consisting of position statement, references.
• Special Treatment Procedure and Special Physics Consult – Revision; updated definitions.
• Stereotactic Body Radiotherapy – Revision; updated position statement, ICD-10 diagnoses codes and definitions. Added position statement for pediatric.
• Stereotactic Radiosurgery (Intracranial) – Revision; updated position statement, ICD-10 diagnoses codes and definitions.
• Temporary Prostatic Stent and Prostatic Urethral Lift – Annual review; PUL coverage statement added; description, coding, & references updated.
• Teriparatide (Forteo®) – Review and revision to guideline; consisting of updating references.
• Tumor/Genetic Markers – Revision; Circulating tumor DNA position statement added; OVA1, Overa, and ROMA tests position statement added and references updated.
• Zoledronic Acid IV (Reclast®, Zometa®) – Review and revision to guideline; consisting of updating position statement, coding and references.

Click here to view the Florida Blue Cross Blue Shield Medical Policy Updates »

Policy Alerts monitors Commercial and Medicare medical policies for changes. While Payers typically update medical policies annually, there are many reasons why a Payer might review or update a policy. When reviews occur out of cycle, they may go unnoticed. Policy Alerts keeps you informed of upcoming and unexpected coverage changes affecting your product. Quickly understanding the changes Payers make can help you adjust reimbursement strategies impacting your business.

Policy Alerts continuously monitors Commercial and Medicare Payer coverage information to keep you up-to-date on Payer decisions in real-time. Whenever changes occur, email notifications containing a summary of those changes are delivered to your inbox. Clients can access detailed coverage reports and medical policies on the interactive Dashboard portal. Save time and keep focused on the important Payer medical policy reviews and coverage decisions affecting your product!

Policy Alerts takes a client-focused hands-on approach and works hard to provide our customers with helpful insights and actionable analytics over raw data. We understand what our clients need and we are dedicated to making sure we provide timely, accurate and always up-to-date reports that can be used to implement and support a successful reimbursement strategy.

Health economic and reimbursement information provided by Policy Alerts is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice.